7 results match your criteria: "University Hospital ASUFC[Affiliation]"
Challenges in chimeric antigen receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma.
Ann Hematol
August 2024
Hematology and Stem Cell Transplantation Unit, University Hospital ASUFC, Udine, Italy.
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study.
Cancers (Basel)
September 2023
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "L. & A. Seràgnoli", 40138 Bologna, Italy.
Article Synopsis
- Blinatumomab (Blina) and inotuzumab ozogamicin (InO) show effectiveness in treating relapsed/refractory B-lymphoblastic leukemia, though outcomes after recurrence and re-treatment are not well understood.
- In a study of 71 patients, those treated with Blina achieved a 63% complete remission (CR) rate, while InO led to an 82% CR rate, highlighting the drugs' potential in handling multiple relapses.
- Overall survival (OS) was 19 months for the Blina/InO group and 9.4 months for the InO/Blina group, with a significant percentage of patients achieving minimal residual disease negativity, indicating promising results as
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE - a multi-centre experience in Italy.
Int J Antimicrob Agents
July 2023
First Division of Infectious Diseases, Cotugno Hospital, Azienda Ospedaliera dei Colli, Naples, Italy.
Background: Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited.
Methods: This multi-centre, observational, ambispective investigator-initiated study was undertaken in Italy from January 2018 to December 2019 in order to evaluate the use of ceftobiprole in a real-world setting.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Cancer Med
May 2023
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Article Synopsis
- Scientists studied older patients with a type of leukemia called acute myeloid leukemia (AML) to find out what factors affect their survival chances.
- They found that early response to treatment and specific health risks can help predict which patients will do better.
- They also discovered that having other health problems, like lung disease or low albumin levels, can make patients weaker and more likely to face complications, influencing how long they might live.
Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
Transpl Infect Dis
April 2023
Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.
Background: Patients undergoing allogeneic stem-cell transplantation (allo-SCT) have reduced responses to vaccines due to immunosuppressive status linked to GvHD prophylaxis and treatment. In our study, we compared humoral responses to anti-SARS-CoV-2 mRNA vaccine, and infection onset, according to patients and transplant features; we also evaluated cellular response in patients without seroconversion.
Methods: We tested antibodies titer after second and third vaccine doses.
Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy.
J Chemother
December 2022
Department of Medical and Surgical Sciences, DIMEC, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Biliary tract cancer's (BTC) treatment main stone for advanced stages is constituted by chemotherapy. Surgical centralization and physicians' confidence in the use of new technologies and molecular analysis turned out to be of interest and potentially influencing survival. After applying a random-effect model, the relationship between each clinical variable on the main outcome was investigated through multilevel mixed-effects logistic regression.
View Article and Find Full Text PDFClinical characteristics and outcome of 125 polymicrobial bloodstream infections in hematological patients: an 11-year epidemiologic survey.
Support Care Cancer
March 2022
Division of Hematology and Stem Cell Transplantation, University Hospital ASUFC, Udine, Italy.
Background: Polymicrobial bloodstream infections (pBSI) occurring in hematological patients are still poorly understood, and specific information are very limited.
Objectives And Methods: In this epidemiologic survey, we describe clinical characteristics and outcome of 125 consecutive pBSI occurred in oncohematological patients. Polymicrobial bloodstream infections (pBSI) were defined with the isolation of 2 or more bacteria from blood culture specimens obtained within 72 h.